» Articles » PMID: 38180107

Exosomal Hsa-miR-151a-3p and Hsa-miR-877-5p Are Potential Novel Biomarkers for Predicting Bone Metastasis in Lung Cancer

Overview
Specialty Geriatrics
Date 2024 Jan 5
PMID 38180107
Authors
Affiliations
Soon will be listed here.
Abstract

Exosomal miRNAs (exo-miRNAs) have arisen as novel diagnostic biomarkers for various cancers. However, few reports on exo-miRNAs related to bone metastasis (BM) in lung cancer exist. This study aims to screen out key exo-miRNAs and estimate their prognostic values for predicting BM in lung cancer. The differentially expressed exo-miRNAs between the highly-metastatic (95D) and lowly-metastatic (A549) human lung cancer cell lines were comprehensively analyzed using high-throughput sequencing followed by bioinformatic analyses. 29 candidate exo-miRNAs were identified, and 101 BM-related target genes were predicted. Enrichment analysis revealed that these target genes were mainly involved in regulating transcription and pathways in cancer. An exosomal miRNA-mRNA regulatory network consisting of 7 key miRNAs and 10 hub genes was constructed. Further function analysis indicated that these 10 hub genes were mainly enriched in regulating cancer's apoptosis and central carbon metabolism. The survival analysis indicated that 7 of 10 hub genes were closely related to prognosis. Mutation analysis showed that lung cancer patients presented certain genetic alterations in the 7 real hub genes. GSEA for a single hub gene suggested that 6 of 7 real hub genes had close associations with lung cancer development. Finally, ROC analysis revealed that hsa-miR-151a-3p and hsa-miR-877-5p provided high diagnostic accuracy in discriminating patients with bone metastasis (BM+) from patients without bone metastasis (BM-). These findings provided a comprehensive analysis of exo-miRNAs and target genes in the regulatory network of BM in lung cancer. In particular, hsa-miR-151a-3p and hsa-miR-877-5p may be novel biomarkers for predicting BM in lung cancer.

Citing Articles

Prognostic risk modeling of endometrial cancer using programmed cell death-related genes: a comprehensive machine learning approach.

Chen T, Yang Y, Huang Z, Pan F, Xiao Z, Gong K Discov Oncol. 2025; 16(1):280.

PMID: 40056247 PMC: 11890841. DOI: 10.1007/s12672-025-02039-8.


Nonylphenol promotes epithelial-mesenchymal transition in colorectal cancer cells by upregulating miR-151a-3p.

Wang B, Zhang N, Dai L, Zhang Y, Yin S, Yang X Discov Oncol. 2025; 16(1):63.

PMID: 39832042 PMC: 11747012. DOI: 10.1007/s12672-025-01805-y.


Molecular Profiling of A549 Cell-Derived Exosomes: Proteomic, miRNA, and Interactome Analysis for Identifying Potential Key Regulators in Lung Cancer.

Giannopoulos-Dimitriou A, Saiti A, Malousi A, Anagnostopoulos A, Vatsellas G, Al-Maghrabi P Cancers (Basel). 2025; 16(24.

PMID: 39766023 PMC: 11674491. DOI: 10.3390/cancers16244123.


New insights into non-small cell lung cancer bone metastasis: mechanisms and therapies.

Xue M, Ma L, Zhang P, Yang H, Wang Z Int J Biol Sci. 2024; 20(14):5747-5763.

PMID: 39494330 PMC: 11528464. DOI: 10.7150/ijbs.100960.


In Silico Identification of Dysregulated miRNAs Targeting Gene in Pancreatic Cancer.

Garibaldi-Rios A, Figuera L, Zuniga-Gonzalez G, Gomez-Meda B, Garcia-Verdin P, Carrillo-Davila I Diseases. 2024; 12(7).

PMID: 39057123 PMC: 11276408. DOI: 10.3390/diseases12070152.

References
1.
Shen W, Song Z, Zhong X, Huang M, Shen D, Gao P . Sangerbox: A comprehensive, interaction-friendly clinical bioinformatics analysis platform. Imeta. 2024; 1(3):e36. PMC: 10989974. DOI: 10.1002/imt2.36. View

2.
Distefano R, Nigita G, Le P, Romano G, Acunzo M, Nana-Sinkam P . Disparities in Lung Cancer: miRNA Isoform Characterization in Lung Adenocarcinoma. Cancers (Basel). 2022; 14(3). PMC: 8833952. DOI: 10.3390/cancers14030773. View

3.
Lin E, Hsu J, Lee T, Hsu C, Lin T, Jan Y . Targeting cancer stemness mediated by BMI1 and MCL1 for non-small cell lung cancer treatment. J Cell Mol Med. 2022; 26(15):4305-4321. PMC: 9401641. DOI: 10.1111/jcmm.17453. View

4.
Keith B, Johnson R, Simon M . HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression. Nat Rev Cancer. 2011; 12(1):9-22. PMC: 3401912. DOI: 10.1038/nrc3183. View

5.
Zhou Y, Wang L, Sun Z, Zhang J, Wang X . Targeting c-kit inhibits gefitinib resistant NSCLC cell growth and invasion through attenuations of stemness, EMT and acquired resistance. Am J Cancer Res. 2021; 10(12):4251-4265. PMC: 7783754. View